| Name | Title | Contact Details |
|---|
Comprehensive Clinical Development is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Eldercare Services, LLC is a Tupelo, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
Medavie EMS is a health care delivery and management company based in Dartmouth, Nova Scotia, Canada. We have a team of management staff that specializes in the areas of project management, planning, education, human resources, communications finance, physical resources, process design, facilitation, reporting, and information technology. Currently, Medavie EMS is responsible to deliver EMS in Nova Scotia, New Brunswick, Prince Edward Island, the District Municipality of Muskoka in Ontario, the Municipality of Chatham-Kent in Ontario, Elgin County in Ontario, Saskatoon and surrounding areas in Saskatchewan, as well as, communities across eastern Alberta. Each of these systems is managed by subsidiary companies which have established contracts with governments (provincial and municipal) or health authorities. In addition, Medavie EMS operates a patient transfer service in Massachusetts headquartered in Boston. Combined these companies directly employ or manage a total staff of approximately 3800, 550 of whom are in the US.